NO20006251L - Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse - Google Patents

Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse

Info

Publication number
NO20006251L
NO20006251L NO20006251A NO20006251A NO20006251L NO 20006251 L NO20006251 L NO 20006251L NO 20006251 A NO20006251 A NO 20006251A NO 20006251 A NO20006251 A NO 20006251A NO 20006251 L NO20006251 L NO 20006251L
Authority
NO
Norway
Prior art keywords
compounds
benzothiepine
preparation
dioxide derivatives
medicaments containing
Prior art date
Application number
NO20006251A
Other languages
English (en)
Other versions
NO327075B1 (no
NO20006251D0 (no
Inventor
Wendelin Frick
Alfons Enhsen
Heiner Glombik
Hubert Heuer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20006251D0 publication Critical patent/NO20006251D0/no
Publication of NO20006251L publication Critical patent/NO20006251L/no
Publication of NO327075B1 publication Critical patent/NO327075B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen angår substituerte benzotiepin-l,l-dioksidderivater og deres syreaddisjonssalter.Det beskrives forbindelser med formel I. hvori,,, R5 og Z har de angitte betydningene, samt deres fysiologisk akseptable salter og fysiologisk funksjonelle derivater samt fremgangsmåte for deres fremstilling. Forbindelsene egner seg f.eks. som hypolipidåmika.
NO20006251A 1998-06-10 2000-12-08 Benzotiepin-1,1-dioksidderivater, fremgangsmate for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse NO327075B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1999/003743 WO1999064409A2 (de) 1998-06-10 1999-05-29 Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (3)

Publication Number Publication Date
NO20006251D0 NO20006251D0 (no) 2000-12-08
NO20006251L true NO20006251L (no) 2001-02-07
NO327075B1 NO327075B1 (no) 2009-04-20

Family

ID=7870440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006251A NO327075B1 (no) 1998-06-10 2000-12-08 Benzotiepin-1,1-dioksidderivater, fremgangsmate for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse

Country Status (25)

Country Link
US (1) US6387944B1 (no)
EP (2) EP1086092B1 (no)
JP (2) JP4374426B2 (no)
KR (2) KR100681721B1 (no)
CN (2) CN1127497C (no)
AR (2) AR018633A1 (no)
AT (2) ATE227715T1 (no)
AU (2) AU753275B2 (no)
BR (2) BR9912188B1 (no)
CA (2) CA2334775C (no)
CZ (2) CZ297989B6 (no)
DE (3) DE19825804C2 (no)
DK (2) DK1086092T3 (no)
ES (2) ES2182535T3 (no)
HU (2) HU229761B1 (no)
ID (2) ID28695A (no)
IL (1) IL140078A (no)
NO (1) NO327075B1 (no)
NZ (1) NZ508681A (no)
PL (2) PL196074B1 (no)
PT (2) PT1086092E (no)
RU (2) RU2215001C2 (no)
TR (2) TR200003634T2 (no)
WO (2) WO1999064410A1 (no)
ZA (2) ZA200007061B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
IL156550A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2003018024A1 (de) * 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) * 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP4424363B1 (en) 2019-02-12 2026-04-29 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4536232A1 (en) 2022-06-09 2025-04-16 Albireo AB Treating hepatitis
CN119487013A (zh) 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4629997A1 (en) 2022-12-09 2025-10-15 Albireo AB Asbt inhibitors in the treatment of renal diseases
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155136T3 (es) * 1994-09-13 2001-05-01 Monsanto Co Nuevas benzotiepinas que tienen actividad como inhibidores del transporte de acido biliar iliaco y la captacion de taurocolato.
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE04010088T1 (de) * 1996-03-11 2005-07-14 G.D. Searle Llc Neue Benzothiepine mit pharmazeutischer Wirkung.
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EP1104416A2 (en) * 1998-08-20 2001-06-06 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents

Also Published As

Publication number Publication date
ATE227715T1 (de) 2002-11-15
BR9912188B1 (pt) 2010-12-14
EP1086092A1 (de) 2001-03-28
HU228570B1 (en) 2013-04-29
KR100681721B1 (ko) 2007-02-15
CN1127497C (zh) 2003-11-12
NO327075B1 (no) 2009-04-20
ATE259372T1 (de) 2004-02-15
AU753275B2 (en) 2002-10-10
JP2002517490A (ja) 2002-06-18
DK1086113T3 (da) 2004-05-24
TR200003634T2 (tr) 2001-06-21
BR9911123A (pt) 2006-01-03
AR018634A1 (es) 2001-11-28
DK1086092T3 (da) 2003-03-10
RU2215001C2 (ru) 2003-10-27
CZ297989B6 (cs) 2007-05-16
EP1086092B1 (de) 2002-11-13
PL344827A1 (en) 2001-11-19
JP2002517491A (ja) 2002-06-18
PL196074B1 (pl) 2007-12-31
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
AU4503199A (en) 1999-12-30
ID26876A (id) 2001-02-15
DE59908522D1 (de) 2004-03-18
CZ20004592A3 (cs) 2001-04-11
HUP0102554A1 (hu) 2001-10-28
CN1152039C (zh) 2004-06-02
WO1999064409A2 (de) 1999-12-16
WO1999064410A1 (de) 1999-12-16
HK1039490A1 (en) 2002-04-26
ZA200007060B (en) 2001-07-18
DE19825804C2 (de) 2000-08-24
HUP0102256A1 (hu) 2001-12-28
AU4501999A (en) 1999-12-30
KR20010052682A (ko) 2001-06-25
IL140078A (en) 2004-08-31
HK1036799A1 (en) 2002-01-18
BR9912188A (pt) 2001-04-10
AR018633A1 (es) 2001-11-28
NO20006251D0 (no) 2000-12-08
DE59903411D1 (de) 2002-12-19
JP3374129B2 (ja) 2003-02-04
ES2215387T3 (es) 2004-10-01
HUP0102256A3 (en) 2002-04-29
AU752633B2 (en) 2002-09-26
CA2334775A1 (en) 1999-12-16
ES2182535T3 (es) 2003-03-01
RU2220141C2 (ru) 2003-12-27
DE19825804A1 (de) 1999-12-16
ID28695A (id) 2001-06-28
HUP0102554A3 (en) 2002-12-28
EP1086113A2 (de) 2001-03-28
PT1086113E (pt) 2004-06-30
IL140078A0 (en) 2002-02-10
CA2334773C (en) 2009-05-26
NZ508681A (en) 2002-06-28
CN1305469A (zh) 2001-07-25
EP1086113B1 (de) 2004-02-11
ZA200007061B (en) 2001-07-18
HU229761B1 (hu) 2014-06-30
CA2334775C (en) 2009-10-13
CZ297925B6 (cs) 2007-05-02
JP4374426B2 (ja) 2009-12-02
US6387944B1 (en) 2002-05-14
TR200003632T2 (tr) 2001-04-20
KR20010052701A (ko) 2001-06-25
CA2334773A1 (en) 1999-12-16
WO1999064409A3 (de) 2000-03-02
CZ20004591A3 (cs) 2001-04-11
PT1086092E (pt) 2003-03-31
BR9911123B1 (pt) 2010-12-14
PL196057B1 (pl) 2007-11-30
CN1305487A (zh) 2001-07-25

Similar Documents

Publication Publication Date Title
NO20044882L (no) Acyl-4-karboksylfenylurinstoffderivater, deres fremstilling og anvendelse
NO20066055L (no) Pyridinderivater
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
NO971471L (no) Nye karboksamider med fungicid aktivitet
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
DK1474406T3 (da) Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
ES2184070T3 (es) Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina.
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
AU2002239344A1 (en) Pyrazolopyridines
ATE248837T1 (de) Chinuclidin-acrylamide
EP1602660A4 (en) AMINO PHOSPHONIC ACID DERIVATIVES, THEIR ADDITIONAL SALTS AND S1P RECEPTOR MODULATORS
NO991206L (no) Benzamidinderivater substituert med sykliske aminosyre- eller sykliske hydroksysyrederivater, og deres anvendelse som antikoagulanter
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
ES2243579T3 (es) Derivados de pirazolopirideno.
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
DK0888271T3 (da) Benzamidinderivater substitueret med aminosyre- og hydroxysyrederivater og deres anvendelse som antikoagulerende midler
ATE468317T1 (de) Herstellung von 1,3-diphenylprop-2-en-1- onderivaten
PL326024A1 (en) Novel derivatives of cyclodepsipeptidic substance pf1022
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer

Legal Events

Date Code Title Description
MK1K Patent expired